Abstract: As a subtype of breast cancer, triple negative breast cancer (TNBC) is characterized by poor prognosis. In the case of chemotherapeutic drug resistance, local recurrence and distant metastasis always occur rapidly due to lack of other effective treatments. Therefore, clinical research on new therapeutic target and targeted therapy of TNBC has become a hot spot. This paper focused on the current research progress of TNBC targeted therapy, including PARP inhibitors, antiangiogenesis, anti-epidermal growth factor receptor, androgen receptor antagonists, immune checkpoint inhibitors and PI3KAKT-mTOR inhibitors, in order to find out the most likely to be the direction of targeted therapy for future development.

Key words: triple negative breast cancer, targeted therapy, review